

# 2024 MA HEDIS Measures Quick Tips

Measure	Requirement	Coding Assistance
<p><b>Controlling Blood Pressure (CBP)</b></p> <p>Percentage of patients aged 18-85, who had a diagnosis of hypertension (HTN) and whose blood pressure was adequately controlled (&lt;140/90) during the measurement year (MY).</p> <p>Exclusions:</p> <ul style="list-style-type: none"> <li>• Hospice, Palliative care, member death, or pregnancy – anytime in MY</li> <li>• ESRD, Dialysis, Nephrectomy(total or partial), Kidney transplant- anytime in history thru 12/31/24</li> <li>• Members 81+ with Frailty on 2 diff. DOS in MY</li> <li>• Members 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> </ul>	<p>Patients with essential hypertension (I10) on two different dates of service from January 1 of the prior year (PY) and June 30 of the (MY) place the member in the denominator.</p> <p>Medical record type – outpatient</p> <p>If multiple BPs are taken on the same day, combine the lowest systolic and diastolic.</p> <p><b>Example:</b> 142/ 82 &amp; 138/ 94 = 138/82</p> <p>Acceptable documentation: vital sign flowsheets, progress note, and consult notes</p> <p>Members self-reported BP’s are acceptable and must have been taken on a digital device, full dates.</p> <p>BP’s cannot be used from these events (not all inclusive):</p> <ul style="list-style-type: none"> <li>■ Inpatient or ED visit</li> <li>■ Taken on the same day as a diagnostic test or procedure that requires a change in the diet or medication on or one day before the test or procedure, except for fasting labs (e.g., colonoscopy, nebulizer treatment with albuterol, lidocaine with epinephrine).</li> </ul>	<p><b>3074F</b> – Systolic BP &lt; 130 mmHg</p> <p><b>3075F</b> – Systolic BP between 130 – 139mmHg</p> <p><b>3077F</b> – Systolic BP ≥ 140 mmHg</p> <p><b>3078F</b> – Diastolic BP &lt; 80 mmHg</p> <p><b>3079F</b> – Diastolic BP between 80 – 89 mmHg</p> <p><b>3080F</b> – Diastolic BP ≥ 90 mmHg</p> <p><b>N18.5</b> – Chronic kidney disease, Stage 5</p> <p><b>N18.6</b> – ESRD</p> <p><b>Z99.2</b> – Dependence on renal dialysis</p> <p><b>Z94.0</b> – History of kidney/renal transplant</p>

Measure	Requirement	Coding Assistance
<p><b>Breast Cancer Screening (BCS-E)</b></p> <p>Females aged 52-74 who had a mammogram performed in the prior 27 months; Oct.1 two years prior to MY thru Dec. 31, MY.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>■ Gender -affirming chest surgery (CPT code 19318) with a diagnosis of gender dysphoria – any time in history thru Dec. 31, MY</li> <li>■ Hospice, Palliative care, Member death – Any time in MY</li> <li>■ Bilateral Mastectomy; Transgender (female to male) w/ evidence of bil. Mastectomy – Anytime in members history thru Dec. 31, MY</li> <li>■ Members 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> </ul>	<p>Acceptable mammograms: Screening, Diagnostic, Digital, Film, or Tomosynthesis 3D</p> <p><b>NEW!</b> Unilateral mammogram meets criteria</p> <p><b>NEW!</b> Transgender members (male to female) are eligible for BCS reporting.</p> <p>Can obtain from outpatient and inpatient records.</p> <p>In lieu of BCS radiology report, acceptable documentation notation of BCS complete with date.</p> <p>Documented BCS event in the past medical history, health maintenance or preventive care sections can be used for reporting.</p> <p>MRI's, Ultrasounds, and Biopsies do not meet criteria.</p>	<p><b>Z90.13</b> – Absence of breast bilaterally</p> <p><b>Z90.12</b> – Absence of left breast</p> <p><b>Z90.11</b> – Absence of right breast</p> <p><b>F64.1</b> – Dual role transvestism</p> <p><b>F64.2</b> – Gender identity disorder of childhood</p> <p><b>F64.8</b> – Other gender identity disorders</p> <p><b>F64.9</b> - Gender identity disorder, unspecified</p> <p><b>Z87.890</b> – Personal history of sex reassignment</p>

Measure	Requirement	Coding Assistance												
<p><b>Colon Cancer Screening (COL-E)</b></p> <p>Patients aged 45 - 75 who had an appropriate screening for colon cancer.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Hospice, Palliative care, members death – Anytime in MY</li> <li>• Colon cancer, or Total colectomy – Anytime in member history thru Dec. 31, MY</li> <li>• Patients 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> </ul>	<table border="1" data-bbox="789 162 1365 625"> <thead> <tr> <th data-bbox="789 162 1117 203">Screening</th> <th data-bbox="1125 162 1365 203">Frequency</th> </tr> </thead> <tbody> <tr> <td data-bbox="789 209 1117 284">Fecal Occult Blood (FOBT)</td> <td data-bbox="1125 209 1365 284">Annually</td> </tr> <tr> <td data-bbox="789 290 1117 324">Cologuard/ FIT-DNA</td> <td data-bbox="1125 290 1365 324">Every three years</td> </tr> <tr> <td data-bbox="789 331 1117 365">Flexible Sigmoidoscopy</td> <td data-bbox="1125 331 1365 365">Every five years</td> </tr> <tr> <td data-bbox="789 371 1117 406">CT Colonography</td> <td data-bbox="1125 371 1365 406">Every five years</td> </tr> <tr> <td data-bbox="789 412 1117 446">Colonoscopy</td> <td data-bbox="1125 412 1365 446">Every ten years</td> </tr> </tbody> </table> <p>Documentation of the specific test and completion date are required.</p> <p>Documentation of pathology or incomplete tests or not specified, include:</p> <ul style="list-style-type: none"> <li>▪ Evidence that the scope advanced beyond splenic flexure meets criteria for colonoscopy.</li> <li>▪ Evidence that the scope advanced into the sigmoid colon for a complete flexible sigmoidoscopy.</li> </ul> <p>Specimens collected via digital rectal exam are <i>not</i> accepted.</p>	Screening	Frequency	Fecal Occult Blood (FOBT)	Annually	Cologuard/ FIT-DNA	Every three years	Flexible Sigmoidoscopy	Every five years	CT Colonography	Every five years	Colonoscopy	Every ten years	<p><b>Z85.038</b> - Personal history of other malignant neoplasm of large intestine</p> <p><b>Z85.048</b> - Personal history of other malignant neoplasm of rectum, rectosigmoid junction, and anus</p> <p><b>C18.0 – C18.9, C19, C20, C21.2, C21.8, C78.5</b> - Colon cancer, active</p>
Screening	Frequency													
Fecal Occult Blood (FOBT)	Annually													
Cologuard/ FIT-DNA	Every three years													
Flexible Sigmoidoscopy	Every five years													
CT Colonography	Every five years													
Colonoscopy	Every ten years													

Measure	Requirement	Coding Assistance
<p><b>Glycemic Status Assessment for Patients With Diabetes (GSD) Formerly HBD</b></p> <p>Members aged 18 – 75 who have Type 1 or Type 2 diabetes and whose A1c or glucose management indicator (GMI) levels in the MY was ≤ 9.0%</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Hospice, palliative care, patients’ death – Anytime in MY</li> <li>• Patients 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff. DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> <li>• Patients 81+ with Frailty on 2 different DOS in MY</li> </ul>	<p>Documentation must include a date when the glycemic status assessment (HbA1c or GMI) was performed/ resulted.</p> <p>GMI values must include documentation of the continuous glucose monitoring data date range used to derive the value. The terminal date in the range should be used to assign the assessment date.</p> <p>Member reported glycemic status assessments are eligible for reporting.</p>	<p><b>3044F</b> – A1c &lt; 7.0%</p> <p><b>3051F</b> - A1c 7.0% - 7.9%</p> <p><b>3052F</b> – A1c 8.0% - 9.0%</p> <p><b>3046F</b> – A1c &gt; 9.0%</p>
<p><b>Kidney Health Evaluation for Patient with Diabetes (KED)</b></p> <p>Members aged 18-85 years of age who have type 1 or type 2 diabetes and received a kidney health evaluation by both an estimated glomerular filtration rate (eGFR) and a urine albumin-creatinine ratio (uACR) in the MY</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Hospice, palliative care, members death – Anytime in MY</li> <li>• ERSD, dialysis – Anytime in history thru Dec. 31, MY</li> <li>• Patients 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff. DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> </ul>	<p>eGFR and a uACR can be completed on the same or different dates of service.</p> <ul style="list-style-type: none"> <li>■ At least one eGFR</li> <li>■ At least one uACR identified by either of the following: <ul style="list-style-type: none"> <li>• Both a quantitative urine albumin test and a urine creatinine test with service dates four days or less apart.</li> <li>• A uACR</li> </ul> </li> </ul>	<p><b>N18.5</b> - Chronic kidney disease Stage 5</p> <p><b>N18.6</b> - End stage renal disease</p> <p><b>Z99.2</b> - Dependence on renal dialysis</p>

Measure	Requirement	Coding Assistance
<p><b>Follow-up after Emergency Department Visit for People with Multiple High-Risk Chronic Conditions (FMC)</b></p> <p>Members aged 18 and older who have multiple high- risk conditions who had a follow-up service within 7 days of an ED visit.</p> <p>ED visits between January 1 – December 24, MY.</p> <p><b>Exclusions:</b></p> <ul style="list-style-type: none"> <li>• Hospice, or members death – Any time in MY</li> <li>• ED visit resulting in an acute or non-acute inpatient care on day of visit or within 7 days after the ED visit</li> </ul>	<p>Eligible chronic conditions diagnoses are those that the member was diagnosed with two or more times during the PY or MY prior to the ED visit:</p> <ul style="list-style-type: none"> <li>▪ Alzheimer’s disease and related disorders</li> <li>▪ Chronic kidney disease</li> <li>▪ COPD and asthma</li> <li>▪ Depression</li> <li>▪ Heart failure</li> <li>▪ Acute myocardial infarction</li> <li>▪ Stroke or TIA</li> </ul> <p>The following visits meet criteria:</p> <ul style="list-style-type: none"> <li>▪ Outpatient, telephone, telehealth visit</li> <li>▪ Transitional care management, case management, or complex case management visit</li> <li>▪ Behavioral health visits and ECT</li> <li>▪ Intensive outpatient, partial hospitalization, observation, or Community Mental Health Center visit</li> </ul>	
<p><b>Medication Adherence for Cholesterol (MAC)</b></p> <p>Members aged &gt; 18 with two fills of a statin any intensity who remained adherent 80% or more through the end of the MY.</p> <p><b>Exclusions:</b></p> <p>Hospice, ESRD</p>	<p>Adherence rate begins on the date of the first fill and denominator eligible on the date of the second fill, with compliance then calculated thru 12/31/MY</p> <p>Members can switch between any one of the drug classifications for the respective measures and still be considered adherent while staying within their refill dates</p>	<p>Captured via pharmacy claims only</p>

Measure	Requirement	Coding Assistance
<p><b>Medication Adherence for Diabetes (MAD)</b></p> <p>Members with 2 fills of diabetic medication (Biguanides, DDP-4, Meglitinides, SGLT2 inhibitors, Sulfonylureas, Thiazolidinedione) who remained adherent 80% or more through the end of MY</p> <p><b>Exclusions:</b> Hospice, ESRD, pharmacy claim for Insulin</p>	<p>Adherence rate begins on the date of the first fill and denominator eligible on the date of the second fill, with compliance then calculated thru 12/31/MY</p> <p>Members can switch between any one of the drug classifications for the respective measures and still be considered adherent while staying within their refill dates</p>	<p>Captured via pharmacy claims only</p>
<p><b>Medication Adherence for Hypertension (MAH)</b></p> <p>Members with 2 fills of ACE, ARB, or DRI medication who remained adherent 80% or more through the end of MY</p> <p><b>Exclusions:</b> Hospice, ESRD, one or more prescription claim of Sacubitril / Valsartan (Entresto)</p>	<p>Adherence rate begins on the date of the first fill and denominator eligible on the date of the second fill, with compliance then calculated thru 12/31/MY</p> <p>Members can switch between any one of the drug classifications for the respective measures and still be considered adherent while staying within their refill dates.</p>	<p>Captured via pharmacy claims only</p>

Measure	Requirement	Coding Assistance																
<p data-bbox="96 155 774 245"><b>Osteoporosis Management in Women who had a Fracture (OMW)</b></p> <p data-bbox="96 269 774 337">Females aged 67 – 85 who suffered a fracture and had either within six months after the fracture:</p> <ul data-bbox="96 370 774 521" style="list-style-type: none"> <li data-bbox="96 370 774 440">▪ Bone mineral density (BMD) test or utpatient, telephone, telehealth visit</li> <li data-bbox="96 448 774 521">▪ Received a prescription of an osteoporosis medication</li> </ul> <p data-bbox="96 578 264 607"><b>Exclusions:</b></p> <ul data-bbox="96 643 774 967" style="list-style-type: none"> <li data-bbox="96 643 774 711">• Hospice, Palliative care, members death – Anytime in MY</li> <li data-bbox="96 743 774 773">• Members 81+ with frailty on 2 diff. DOS in MY</li> <li data-bbox="96 805 774 967">• Members 66+ with Advanced Illness and Frailty: <ul data-bbox="96 854 774 967" style="list-style-type: none"> <li data-bbox="96 854 774 883">- Frailty diagnosis on 2 diff. DOS in MY <b>AND</b></li> <li data-bbox="96 891 774 920">- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li data-bbox="96 928 774 958">- Dispensed a dementia medication</li> </ul> </li> </ul>	<p data-bbox="779 155 1425 228"><b>MY- is from July 1 prior year thru June 30 current year.</b></p> <p data-bbox="779 261 1425 329">Fractures of the fingers, toes, face, or skull are not included in this measure.</p> <p data-bbox="779 362 1425 391">Medical records – Inpatient and outpatient</p> <p data-bbox="779 423 1425 453">Must include the date the test was completed.</p> <p data-bbox="779 485 1425 553">BMD test 730 days (2 years) prior to the fracture date will remove member from the denominator.</p> <p data-bbox="779 586 1425 740">Members with a pharmacy claim or an active prescription of an osteoporosis medication during the 365 days prior to the fracture date will remove the member from the denominator.</p>	<table border="1" data-bbox="1438 155 1959 1174"> <thead> <tr> <th colspan="2" data-bbox="1438 155 1959 196">Osteoporosis Medication</th> </tr> </thead> <tbody> <tr> <td data-bbox="1438 199 1682 277"><b>J0897</b></td> <td data-bbox="1686 199 1959 277">Injection, denosumab, 1mg</td> </tr> <tr> <td data-bbox="1438 280 1682 399"><b>J1740</b></td> <td data-bbox="1686 280 1959 399">Injection, ibandronate sodium, 1mg</td> </tr> <tr> <td data-bbox="1438 402 1682 480"><b>J3110</b></td> <td data-bbox="1686 402 1959 480">Injection, teriparatide, 10mg</td> </tr> <tr> <td data-bbox="1438 483 1682 594"><b>J3111</b></td> <td data-bbox="1686 483 1959 594">Injection, Romosozumab, 1mg</td> </tr> <tr> <td data-bbox="1438 597 1682 675"><b>J3489</b></td> <td data-bbox="1686 597 1959 675">Injection, zoledronic acid, 1mg</td> </tr> <tr> <td data-bbox="1438 678 1682 919"><b>Bisphosphonates</b></td> <td data-bbox="1686 678 1959 919"> <ul data-bbox="1686 686 1959 919" style="list-style-type: none"> <li data-bbox="1686 686 1959 716">• Alendronate</li> <li data-bbox="1686 724 1959 792">• Alendronate-cholecalciferol</li> <li data-bbox="1686 800 1959 829">• Ibandronate</li> <li data-bbox="1686 837 1959 867">• Risedronate</li> <li data-bbox="1686 875 1959 919">• Zoledronic acid</li> </ul> </td> </tr> <tr> <td data-bbox="1438 922 1682 1174"><b>Other Agents</b></td> <td data-bbox="1686 922 1959 1174"> <ul data-bbox="1686 930 1959 1138" style="list-style-type: none"> <li data-bbox="1686 930 1959 959">• Abaloparatide</li> <li data-bbox="1686 967 1959 997">• Denosumab</li> <li data-bbox="1686 1005 1959 1034">• Raloxifene</li> <li data-bbox="1686 1042 1959 1071">• Romosozumab</li> <li data-bbox="1686 1079 1959 1109">• Teriparatide</li> </ul> </td> </tr> </tbody> </table>	Osteoporosis Medication		<b>J0897</b>	Injection, denosumab, 1mg	<b>J1740</b>	Injection, ibandronate sodium, 1mg	<b>J3110</b>	Injection, teriparatide, 10mg	<b>J3111</b>	Injection, Romosozumab, 1mg	<b>J3489</b>	Injection, zoledronic acid, 1mg	<b>Bisphosphonates</b>	<ul data-bbox="1686 686 1959 919" style="list-style-type: none"> <li data-bbox="1686 686 1959 716">• Alendronate</li> <li data-bbox="1686 724 1959 792">• Alendronate-cholecalciferol</li> <li data-bbox="1686 800 1959 829">• Ibandronate</li> <li data-bbox="1686 837 1959 867">• Risedronate</li> <li data-bbox="1686 875 1959 919">• Zoledronic acid</li> </ul>	<b>Other Agents</b>	<ul data-bbox="1686 930 1959 1138" style="list-style-type: none"> <li data-bbox="1686 930 1959 959">• Abaloparatide</li> <li data-bbox="1686 967 1959 997">• Denosumab</li> <li data-bbox="1686 1005 1959 1034">• Raloxifene</li> <li data-bbox="1686 1042 1959 1071">• Romosozumab</li> <li data-bbox="1686 1079 1959 1109">• Teriparatide</li> </ul>
Osteoporosis Medication																		
<b>J0897</b>	Injection, denosumab, 1mg																	
<b>J1740</b>	Injection, ibandronate sodium, 1mg																	
<b>J3110</b>	Injection, teriparatide, 10mg																	
<b>J3111</b>	Injection, Romosozumab, 1mg																	
<b>J3489</b>	Injection, zoledronic acid, 1mg																	
<b>Bisphosphonates</b>	<ul data-bbox="1686 686 1959 919" style="list-style-type: none"> <li data-bbox="1686 686 1959 716">• Alendronate</li> <li data-bbox="1686 724 1959 792">• Alendronate-cholecalciferol</li> <li data-bbox="1686 800 1959 829">• Ibandronate</li> <li data-bbox="1686 837 1959 867">• Risedronate</li> <li data-bbox="1686 875 1959 919">• Zoledronic acid</li> </ul>																	
<b>Other Agents</b>	<ul data-bbox="1686 930 1959 1138" style="list-style-type: none"> <li data-bbox="1686 930 1959 959">• Abaloparatide</li> <li data-bbox="1686 967 1959 997">• Denosumab</li> <li data-bbox="1686 1005 1959 1034">• Raloxifene</li> <li data-bbox="1686 1042 1959 1071">• Romosozumab</li> <li data-bbox="1686 1079 1959 1109">• Teriparatide</li> </ul>																	

Measure	Requirement	Coding Assistance
<p data-bbox="96 142 655 180"><b>Plan All-Cause Readmissions (PCR)</b></p> <p data-bbox="96 207 768 394">For members 18 years of age and older, the number of acute inpatient and observation stays between January 1st and December 1st of MY, that were followed by an unplanned acute readmission for any diagnosis, within 30 days of discharge.</p> <p data-bbox="96 431 247 456"><b>Exclusions:</b></p> <ul data-bbox="96 472 768 1105" style="list-style-type: none"> <li data-bbox="96 472 436 496">• Hospice – Anytime in MY</li> <li data-bbox="96 532 625 557">• Hospital stays where the patient expired</li> <li data-bbox="96 592 747 662">• Principal diagnosis of pregnancy on the discharge claim</li> <li data-bbox="96 698 768 768">• Principal diagnosis of a condition originating in the perinatal period on the discharge claim</li> <li data-bbox="96 803 768 1105">• Acute hospitalizations where the discharge claims has a diagnosis for: <ul style="list-style-type: none"> <li data-bbox="121 898 495 922">- Chemotherapy maintenance</li> <li data-bbox="121 946 583 971">- Principal diagnosis of rehabilitation</li> <li data-bbox="121 1003 352 1027">- Organ transplant</li> <li data-bbox="121 1060 768 1105">- Potentially planned procedure without a principal acute diagnosis</li> </ul> </li> </ul>	<p data-bbox="779 147 1308 217">This measure is based on discharges, not members.</p> <p data-bbox="779 253 1398 323">Behavioral health discharges are included in this measure.</p>	<p data-bbox="1430 147 1759 172">Captured via claims only.</p>



Measure	Requirement	Coding Assistance																																		
<p><b>Statin Therapy for Patients with Cardiovascular Disease (SPC)</b></p> <p>Males aged 21 – 75 and females aged 40 – 75, who are identified as having clinical ASCVD and who had at least one high-intensity or moderate-intensity statin dispensed in the MY.</p> <p><b>Exclusions PY or MY:</b> Pregnancy, In vitro fertilization, ESRD, Dialysis, Cirrhosis, one claim for clomiphene</p> <p><b>Exclusions MY:</b> Hospice, Palliative care, Members death, Myalgia, Myositis, Myopathy, Rhabdomyolysis</p> <ul style="list-style-type: none"> <li>Members 66+ with Advanced Illness and Frailty: <ul style="list-style-type: none"> <li>- Frailty diagnosis on 2 diff. DOS in MY <b>AND</b></li> <li>- Advanced Illness on 2 diff. DOS in PY or MY <b>OR</b></li> <li>- Dispensed a dementia medication</li> </ul> </li> </ul>	<p>Inclusion event and/or diagnosis in the PY: MI, CABG, PCI or other revascularization, or IVD</p> <p>Inclusion diagnosis of IVD in the PY and MY</p> <table border="1" data-bbox="789 305 1383 1162"> <thead> <tr> <th data-bbox="789 305 1062 386">High-intensity Statin Therapy</th> <th data-bbox="1062 305 1383 386">Moderate-intensity Statin Therapy</th> </tr> </thead> <tbody> <tr> <td data-bbox="789 386 1062 472"> <ul style="list-style-type: none"> <li>Atorvastatin 40 – 80mg</li> </ul> </td> <td data-bbox="1062 386 1383 472"> <ul style="list-style-type: none"> <li>Atorvastatin 10 – 20mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 472 1062 581"> <ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 40 – 80mg</li> </ul> </td> <td data-bbox="1062 472 1383 581"> <ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 10 – 20mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 581 1062 673"> <ul style="list-style-type: none"> <li>Rosuvastatin 20 – 40mg</li> </ul> </td> <td data-bbox="1062 581 1383 673"> <ul style="list-style-type: none"> <li>Rosuvastatin 5 – 10mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 673 1062 766"> <ul style="list-style-type: none"> <li>Simvastatin 80mg</li> </ul> </td> <td data-bbox="1062 673 1383 766"> <ul style="list-style-type: none"> <li>Simvastatin 20 – 40mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 766 1062 862"> <ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 80mg</li> </ul> </td> <td data-bbox="1062 766 1383 862"> <ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 20 – 40mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 862 1062 935"></td> <td data-bbox="1062 862 1383 935"> <ul style="list-style-type: none"> <li>Pravastatin 40 – 80mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 935 1062 1008"></td> <td data-bbox="1062 935 1383 1008"> <ul style="list-style-type: none"> <li>Lovastatin 40mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 1008 1062 1081"></td> <td data-bbox="1062 1008 1383 1081"> <ul style="list-style-type: none"> <li>Fluvastatin 40 – 80mg</li> </ul> </td> </tr> <tr> <td data-bbox="789 1081 1062 1162"></td> <td data-bbox="1062 1081 1383 1162"> <ul style="list-style-type: none"> <li>Pitavastatin 1 – 4mg</li> </ul> </td> </tr> </tbody> </table>	High-intensity Statin Therapy	Moderate-intensity Statin Therapy	<ul style="list-style-type: none"> <li>Atorvastatin 40 – 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Atorvastatin 10 – 20mg</li> </ul>	<ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 40 – 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 10 – 20mg</li> </ul>	<ul style="list-style-type: none"> <li>Rosuvastatin 20 – 40mg</li> </ul>	<ul style="list-style-type: none"> <li>Rosuvastatin 5 – 10mg</li> </ul>	<ul style="list-style-type: none"> <li>Simvastatin 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Simvastatin 20 – 40mg</li> </ul>	<ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 20 – 40mg</li> </ul>		<ul style="list-style-type: none"> <li>Pravastatin 40 – 80mg</li> </ul>		<ul style="list-style-type: none"> <li>Lovastatin 40mg</li> </ul>		<ul style="list-style-type: none"> <li>Fluvastatin 40 – 80mg</li> </ul>		<ul style="list-style-type: none"> <li>Pitavastatin 1 – 4mg</li> </ul>	<table border="1" data-bbox="1440 147 1986 1024"> <thead> <tr> <th data-bbox="1440 147 1686 191">Exclusion</th> <th data-bbox="1686 147 1986 191">ICD-10 Code</th> </tr> </thead> <tbody> <tr> <td data-bbox="1440 191 1686 272"><b>Myalgia</b></td> <td data-bbox="1686 191 1986 272">M79.10 - M79.12, M79.18</td> </tr> <tr> <td data-bbox="1440 272 1686 610"><b>Myositis</b></td> <td data-bbox="1686 272 1986 610">M60.80-M60.819; M60.821-M60.829; M60.831-M60.839; M60.841-M60.849; M60.851-M60.859; M60.861-M60.869; M60.871-M60.879, M60.88, M60.89, M60.9</td> </tr> <tr> <td data-bbox="1440 610 1686 670"><b>Myopathy</b></td> <td data-bbox="1686 610 1986 670">G72.0, G72.2, G72.9</td> </tr> <tr> <td data-bbox="1440 670 1686 764"><b>Rhabdomyolysis</b></td> <td data-bbox="1686 670 1986 764">M62.82</td> </tr> <tr> <td data-bbox="1440 764 1686 927"><b>Cirrhosis</b></td> <td data-bbox="1686 764 1986 927">K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81</td> </tr> <tr> <td data-bbox="1440 927 1686 1024"><b>ESRD</b></td> <td data-bbox="1686 927 1986 1024">N18.5, N18.6, Z99.2</td> </tr> </tbody> </table>	Exclusion	ICD-10 Code	<b>Myalgia</b>	M79.10 - M79.12, M79.18	<b>Myositis</b>	M60.80-M60.819; M60.821-M60.829; M60.831-M60.839; M60.841-M60.849; M60.851-M60.859; M60.861-M60.869; M60.871-M60.879, M60.88, M60.89, M60.9	<b>Myopathy</b>	G72.0, G72.2, G72.9	<b>Rhabdomyolysis</b>	M62.82	<b>Cirrhosis</b>	K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81	<b>ESRD</b>	N18.5, N18.6, Z99.2
High-intensity Statin Therapy	Moderate-intensity Statin Therapy																																			
<ul style="list-style-type: none"> <li>Atorvastatin 40 – 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Atorvastatin 10 – 20mg</li> </ul>																																			
<ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 40 – 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Amlodipine-atorvastatin 10 – 20mg</li> </ul>																																			
<ul style="list-style-type: none"> <li>Rosuvastatin 20 – 40mg</li> </ul>	<ul style="list-style-type: none"> <li>Rosuvastatin 5 – 10mg</li> </ul>																																			
<ul style="list-style-type: none"> <li>Simvastatin 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Simvastatin 20 – 40mg</li> </ul>																																			
<ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 80mg</li> </ul>	<ul style="list-style-type: none"> <li>Ezetimibe-simvastatin 20 – 40mg</li> </ul>																																			
	<ul style="list-style-type: none"> <li>Pravastatin 40 – 80mg</li> </ul>																																			
	<ul style="list-style-type: none"> <li>Lovastatin 40mg</li> </ul>																																			
	<ul style="list-style-type: none"> <li>Fluvastatin 40 – 80mg</li> </ul>																																			
	<ul style="list-style-type: none"> <li>Pitavastatin 1 – 4mg</li> </ul>																																			
Exclusion	ICD-10 Code																																			
<b>Myalgia</b>	M79.10 - M79.12, M79.18																																			
<b>Myositis</b>	M60.80-M60.819; M60.821-M60.829; M60.831-M60.839; M60.841-M60.849; M60.851-M60.859; M60.861-M60.869; M60.871-M60.879, M60.88, M60.89, M60.9																																			
<b>Myopathy</b>	G72.0, G72.2, G72.9																																			
<b>Rhabdomyolysis</b>	M62.82																																			
<b>Cirrhosis</b>	K70.30, K70.31, K71.7, K74.3-K74.5, K74.60, K74.69, P78.81																																			
<b>ESRD</b>	N18.5, N18.6, Z99.2																																			

Measure	Requirement	Coding Assistance													
<p data-bbox="96 155 779 196"><b>Statin Use in Patients with Diabetes (SUPD)</b></p> <p data-bbox="96 220 747 293">Members aged 40 – 75 with diabetes, who receive at least one fill of a statin medication in MY.</p> <p data-bbox="96 318 247 342"><b>Exclusions:</b></p> <p data-bbox="96 358 699 472">Hospice, ESRD, Dialysis, Pregnancy, Lactation, In vitro fertilization, Pre-diabetes, PCOS, Cirrhosis, Rhabdomyolysis, Myopathy</p>	<p data-bbox="800 155 1325 188">Any statin at any intensity meets criteria.</p>	<table border="1"> <thead> <tr> <th data-bbox="1417 164 1654 204">Exclusion</th> <th data-bbox="1661 164 1992 204">ICD-10 Code</th> </tr> </thead> <tbody> <tr> <td data-bbox="1417 204 1654 326"><b>Myopathy</b></td> <td data-bbox="1661 204 1992 326">G72.0, G72.89, G72.9</td> </tr> <tr> <td data-bbox="1417 326 1654 480"><b>Myositis</b></td> <td data-bbox="1661 326 1992 480">M60.80, M60.819, M60.829, M60.839, M60.849, M60.859, M60.869, M60.879, M60.9</td> </tr> <tr> <td data-bbox="1417 480 1654 570"><b>Rhabdomyolysis</b></td> <td data-bbox="1661 480 1992 570">M62.82</td> </tr> <tr> <td data-bbox="1417 570 1654 732"><b>Cirrhosis</b></td> <td data-bbox="1661 570 1992 732">K70.30, K70.31, K71.7, K74.3 -5, K74.60, K74.69</td> </tr> <tr> <td data-bbox="1417 732 1654 886"><b>ESRD</b></td> <td data-bbox="1661 732 1992 886">I12.0, I13.11, I13.2, N18.5, N18.6, N19, Z91.15, Z99.2</td> </tr> </tbody> </table>	Exclusion	ICD-10 Code	<b>Myopathy</b>	G72.0, G72.89, G72.9	<b>Myositis</b>	M60.80, M60.819, M60.829, M60.839, M60.849, M60.859, M60.869, M60.879, M60.9	<b>Rhabdomyolysis</b>	M62.82	<b>Cirrhosis</b>	K70.30, K70.31, K71.7, K74.3 -5, K74.60, K74.69	<b>ESRD</b>	I12.0, I13.11, I13.2, N18.5, N18.6, N19, Z91.15, Z99.2	
Exclusion	ICD-10 Code														
<b>Myopathy</b>	G72.0, G72.89, G72.9														
<b>Myositis</b>	M60.80, M60.819, M60.829, M60.839, M60.849, M60.859, M60.869, M60.879, M60.9														
<b>Rhabdomyolysis</b>	M62.82														
<b>Cirrhosis</b>	K70.30, K70.31, K71.7, K74.3 -5, K74.60, K74.69														
<b>ESRD</b>	I12.0, I13.11, I13.2, N18.5, N18.6, N19, Z91.15, Z99.2														

Measure	Requirement	Coding Assistance
<p><b>Transition of Care (TRC)</b></p> <p>Members aged 18 and greater, who had an acute or non-acute inpatient discharge on or between January 1st and December 1st of MY and each of the following:</p> <ul style="list-style-type: none"> <li>■ Notification of Inpatient Admission (NIA)</li> <li>■ Receipt of Discharge Information (RDI)</li> <li>■ Patient Engagement after Inpatient Discharge (PED)</li> <li>■ Medication Reconciliation Post-discharge (MRP)</li> </ul> <p><b>Exclusions:</b> Hospice or members death - Anytime in MY</p>	<p><b>NIA</b> and <b>RDI</b> must have evidence that the documentation is added, scanned, or received in the outpatient medical record.</p> <p>Communication between inpatient providers, staff, emergency department and PCP/OCP.</p> <p>Communication from the health plan, specialists, or shared EMR to the PCP/OCP regarding the patients admission.</p> <p><b>NIA:</b> Documentation/ evidence of notification of admission on the day of or up to two days after admission – total of 3 days</p> <p>Documentation of a pre-admission exam received communication of a planned inpatient admission is not limited to the NIA timeframe.</p> <p><b>RDI:</b> Documentation must include:</p> <ul style="list-style-type: none"> <li>■ The practitioner responsible for care</li> <li>■ Procedures or treatments provided</li> <li>■ Diagnoses at discharge</li> <li>■ Current medication list</li> <li>■ Test results, pending tests or no tests pending</li> <li>■ Instructions for patient care post discharge</li> </ul> <p><b>PE:</b> Office visit, Home visit, Telehealth visit within 30 days after discharge</p> <p><b>MRP:</b> Medication reconciliation on date of D/C through 30 days after discharge; member does not need to be present for MRP to be completed.</p>	<p><b>1111F</b> - discharge meds reconciled with current medication list</p> <p><b>99483, 99495, 99496</b> - Transitional Care Management Services (TCM) includes medication reconciliation</p>

Arkansas Blue Medicare is an affiliate of Arkansas Blue Cross and Blue Shield. Arkansas Blue Cross and Blue Shield is an Independent Licensee of the Blue Cross and Blue Shield Association. © 2023 Arkansas Blue Cross and Blue Shield. All rights reserved.